Kudrna's Stock Market Talk

This morning, InVivo Therapeutics (NVIV) announced significant news relating to the advancement of the company’s biopolymer scaffolding device to treat acute spinal cord injury. Management recently met with the U.S. FDA to discuss the Investigational Device Expemption (IDE) and the planned human clinical study. Talks centered around the inclusion / exclusion criteria, along with defining the starting and stopping points for the trial. This is a first of its kind program, and one that we’ve written about previously as being potentially revolutionary for the treatment of acute spinal cord injury. Read the rest of this entry »

Quote of the Day:

The expropriation is nothing more than a way of covering over the social and economic crisis facing Argentina right now.

Antonio Brufau – Repsol Chairman. Read the rest of this entry »

We recommend investors keep an eye on Spherix, Inc. (SPEX). The stock has a history of quick rallies on news, followed by quick sell-offs on subsequent dilutive financings. The company has several catalysts coming up over the next few quarters that could provide meaningful opportunities for investors. Read the rest of this entry »

Quote of the Day:

Spain has absolutely no financing problems or urgent needs.

Luis de Guindos – Spanish Economy Minister Read the rest of this entry »

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix it to break-even. Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  Read the rest of this entry »

On May 4, 2012, the U.S. FDA is expected to rule on the approval of Alexza Pharmaceuticals’ (ALXA) Adasuve (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and bipolar disorder. The decision has already been delayed by three months from the original (“PDUFA”) action date set by the FDA of February 4, 2012. I view the decision as make-or-break for Alexza, a company that has already significantly reduced its staff in an effort to limit operating burn ahead of the decision. Read the rest of this entry »

Quote of the Day:

They [Arsenal] have a replay against Chelsea and if they win it they would face a semi-final three days before playing us in the league. But then they did say they were going to win the Treble, didn’t they? It’s squeaky bum time and we’ve got the experience now to cope.

Sir Alex Ferguson – Manchester United Manager Read the rest of this entry »

Quote of the Day:

Today there’s speculation the ECB will jump in. You know what? That will be one of the worst possible things to happen to medium term confidence for the markets. As soon as the ECB steps in, resumes the SMP buying program it’s a clear signal that nothing is fixed…

Bill Blain – Newedge Group Read the rest of this entry »

On April 10, 2012, Titan Pharmaceuticals (TTNP) announced it has entered into a definiative agreement to issue 6.517 million shares of common stock to institutional investors at $0.85 per share. The registered direct offering will provide gross proceeds of approximately $5.5 million in cash to Titan. Titan plans to use the proceeds to fund the preparation of a NDA for Probuphine, expected in October 2012, along with working capital and general corporate purposes. Read the rest of this entry »

Quote of the Day:

Superman where are you now
Everything’s gone wrong somehow
The men of steel, men of power
Are losing control by the hour.

This is the time
This is the place
So we look for the future
But there’s not much love to go round
Tell me why, this is a land of confusion.

Phil Collins – Land of Confusion Read the rest of this entry »